Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial

@article{Castagno2010ImprovedSW,
  title={Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial},
  author={Davide Castagno and Pardeep S. Jhund and John J. V. McMurray and James Lewsey and Erland Erdmann and Faiez Zannad and Willem J. Remme and Jos{\'e} Luis L{\'o}pez-Send{\'o}n and Philippe P Lechat and Ferenc Follath and Christer H{\"o}glund and Viacheslav Mareev and Zygmunt P Sadowski and Ricardo J. Seabra-Gomes and Henry J. Dargie},
  journal={European Journal of Heart Failure},
  year={2010},
  volume={12}
}
Information on the effectiveness of beta‐blockade in patients with heart failure (HF) and concomitant renal impairment is scarce and beta‐blockers are underutilized in these patients. 
Cardiorenal syndrome: Pathophysiology, preclinical models, management and potential role of uraemic toxins
1. Cardiorenal syndrome (CRS) describes the primary dysfunction in either the kidney or heart that initiates the combined impairment of both organs. The heart and kidney exert reciprocal control ofExpand
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.
TLDR
Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction, according to renal function using estimated glomerular filtration rate (eGFR). Expand
The Acute Cardiorenal Syndrome: Burden and Mechanisms of Disease
TLDR
Emerging data support therapeutic strategies that permit WRF while effectively treating congestion as they are associated with improved outcomes. Expand
University of Birmingham Impact of renal impairment on beta-blocker efficacy in patients with heart failure
ISS Fro cu Fa Nu Kin Ins Pis Sa W D Ca Un BACKGROUND Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockersExpand
Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease.
TLDR
This review evaluated recent evidence for the use of GDMT in patients with HFrEF and advanced CKD approaching dialysis from RCTs and observational cohorts and offers guidance to clinicians for proper clinical use and future research directions. Expand
We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
  • N. Matsuda
  • Medicine
  • Circulation journal : official journal of the Japanese Circulation Society
  • 2010
TLDR
Fear of adverse potential and limited information about long-term effects and tolerability might explain the clinical hesitation to administer β-blockers for heart failure and concomitant chronic kidney disease. Expand
University of Groningen Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Beta-Blockers Heart Failure
ISS Fro cu Fa Nu Kin Ins Pis Sa W D Ca Un BACKGROUND Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockersExpand
Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study.
TLDR
The data suggested that anemia was associated with a blunted response to carvedilol in HFrEF patients, and was an independent predictor of the composite endpoint of death, hospitalization for cardiovascular causes including HF. Expand
Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease
TLDR
In HFrEF patients with advanced CKD, the use of β-blocker was associated with lower morbidity and mortality, although inconclusive due to limited power, these benefits were not observed in similar patients with HFpEF or HFmrEF. Expand
Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease
Results Eight trials met criteria for review: 6 placebo-controlled trials involving 5,972 participants with chronic systolic heart failure and 2 angiotensin-converting enzyme inhibitor–comparatorExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
TLDR
To determine the safety and efficacy of nebivolol in elderly heart failure (HF) patients with renal dysfunction, a large number of patients with kidney dysfunction are treated with this drug. Expand
Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure
TLDR
Analysis in high‐risk subgroups of patients taking part in CIBIS II have been performed to investigate the effect of bisoprolol in elderly patients, in patients with type 2 diabetes, with renal failure, NYHA functional class IV or concomitantly treated with digitalis, aldosterone antagonists or amiodarone. Expand
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
TLDR
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients. Expand
Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee.
  • Medicine
  • Fundamental & clinical pharmacology
  • 1997
TLDR
The objective of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II) is to evaluate effects of the selective beta-1 adrenoceptor blocker, bisoproll, on mortality (primary endpoint) in patients with ischaemic or non-ischaemic chronic heart failure. Expand
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
TLDR
Renal insufficiency is common in patients with HF and coronary artery disease, and these patients have more advanced coronary atherosclerosis, and they are less likely to be prescribed efficacious therapies, but have better outcomes if they receive these medications. Expand
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality.
TLDR
In dialysis patients without a previous documented history of heart failure, beta-blocker use was associated with a lower risk of new HF, cardiovascular death, and death from any cause, and no such associations were seen for Dialysis patients with a previous history of HF. Expand
Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
TLDR
Impaired renal function (GFR(c)) is a stronger predictor of mortality than impaired cardiac function (LVEF and New York Heart Association class) in advanced CHF, and it is associated with increased levels of N-terminal ANP. Expand
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
BACKGROUND The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven. However, itsExpand
Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study
TLDR
Renal insufficiency is more prevalent in patients with heart failure than previously reported and is an independent prognostic factor in diastolic and systolic dysfunction. Expand
Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival.
TLDR
GFRc is related to survival and plasma neurohormones in both patient groups, and in patients with IDC, this association appears to be at least as strong as in Patients with CAD. Expand
...
1
2
3
4
5
...